Loading stock data…
VRDN
$17.20+0.59 (+3.55%)
Pre-Market$17.35+0.15 (+0.87%)· Last close May 11
Viridian Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Viridian Therapeutics, Inc. in the Healthcare sector is trading at $17.20. The stock is currently 50% below its 52-week high of $34.29, remaining 29.3% below its 200-day moving average. Technical signals show neutral RSI of 65 and bullish MACD crossover, explaining why VRDN maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 65) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$17.20
Potential Upside
5%
Whystock Fair Value$18.06
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus16 analysts
Mean target$34.56+100.9%
Range$20.00 – $50.00
Fundamentals
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclona...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.47B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.17
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-47.44%
Volume
Today's trading volume
3.21M
Recent News
Why Viridian Therapeutics (VRDN) Is Up 25.9% After Phase 3 Elegrobart Win And Fresh Fundraising
Viridian Therapeutics recently reported positive topline results from its REVEAL‑2 phase 3 trial of elegrobart in chronic thyroid eye disease, while also completing US$125,000,014 of common stock and US$225,000,000 of convertible note offerings to support its pipeline and launch preparations. The company is now positioned with two late-stage IGF‑1R antibody programs for thyroid eye disease, veligrotug nearing an FDA decision and elegrobart advancing toward a planned 2027 biologics license...
Earnings Update: Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Are Boosting Their Estimates
A week ago, Viridian Therapeutics, Inc. ( NASDAQ:VRDN ) came out with a strong set of first-quarter numbers that could...
Viridian Therapeutics’ stock up 35% after Phase III TED data release
Viridian is in the process of filing a BLA for its TED candidate elegrobart based on two positive Phase III trials.
Viridian Therapeutics REVEAL-2 Hits Phase 3 Endpoint, Shows “IV-like” Proptosis Gains in Chronic TED
Viridian Therapeutics (NASDAQ:VRDN) reported positive top-line results from REVEAL-2, a Phase 3 pivotal trial evaluating subcutaneous elegrobart (Ellay) in patients with chronic thyroid eye disease (TED), saying the study met its primary endpoint with “IV-like” improvements in proptosis and showed m
Viridian (VRDN) Climbs 33% on Looming Drug Commercialization
Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the 10 Stocks Turning Heads With Double-Digit Gains. Viridian Therapeutics extended gains for a second day on Tuesday, soaring 33.36 percent to close at $18.75 apiece, as investor sentiment was bolstered by the looming commercialization of its eye disease treatment. In an updated report, Viridian Therapeutics Inc. (NASDAQ:VRDN) […]